Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two Annamycin treatment arms, compared to 12% in placebo, with no signs of cardiotoxicity. The independent Data Monitoring Committee recommended continuing the trial without changes. These results support Annamycin's potential as a safer, effective AML treatment, with further analysis expected in early 2027.
Moleculin's Annamycin trial data presentation is noted here alongside Pluang's health sector market snapshot as of Nov 04, 2026 23:12 WIB: out of 150 health stocks, 106 rose and 43 fell. Notable movers include Tilray Brands Inc (TLRY) with a price of USD 2.95 and a 1-day change of +11.32%, Nuwellis Inc (NUWE) at USD 5.31 down -10.15%, and Moderna, Inc. (MRNA) at USD 250.38 up +9.60%.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
The global AI accelerator market is projected to grow from $151 billion in 2025 to $443 billion by 2030, with a compound annual growth rate of about 24%. This expansion is fueled by the rise of generative AI, large language models, and increased inve...
